<p>Voya Investment Management LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度将其在 Madrigal Pharmaceuticals, Inc.（NASDAQ:MDGL - 免费报告）中的股份削减了 77.2%。该基金在此期间售出了 33,672 股后，持有 9,942 股该生物制药公司的股票。Voya Investment Management LLC 在 Madrigal Pharmaceuticals 的持股在最近一个季度末价值 306.8 万美元。</p>
<ul>
<li>诺和诺德：GLP-1 销售的新动力即将到来</li>
</ul>
<p>其他机构投资者最近也增持或减持了该公司的股份。FMR LLC 在第四季度将其在 Madrigal Pharmaceuticals 的股份增加了 10.8%。FMR LLC 目前持有 867,850 股该生物制药公司的股票，价值 267,792,000 美元，此前在上个季度增持了 84,305 股。Geode Capital Management LLC 在第四季度将其在 Madrigal Pharmaceuticals 的股份增加了 1.2%。Geode Capital Management LLC 目前持有 410,578 股该生物制药公司的股票，价值 126,719,000 美元，此前增持了 4,923 股。William Blair Investment Management LLC 在第四季度购买了 Madrigal Pharmaceuticals 的新头寸，价值 114,717,000 美元。Rock Springs Capital Management LP 在第四季度将其在 Madrigal Pharmaceuticals 的持仓提高了 0.8%。Rock Springs Capital Management LP 目前持有 265,212 股该生物制药公司的股票，价值 81,836,000 美元，此前增持了 2,150 股。最后，Pictet Asset Management Holding SA 在第四季度将其在 Madrigal Pharmaceuticals 的持股提高了 38.4%。Pictet Asset Management Holding SA 目前持有 208,484 股该生物制药公司的股票，价值 64,332,000 美元，此前增持了 57,886 股。对冲基金和其他机构投资者持有该公司 98.50% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>MDGL 已经成为多份研究报告的主题。JMP Securities 在 4 月 24 日的研究报告中重申了对 Madrigal Pharmaceuticals 的 “市场表现优于大盘” 评级，并给出了 443.00 美元的目标价。B. Riley 在周五重新发布了 “买入” 评级，并将 Madrigal Pharmaceuticals 的目标价从 422.00 美元上调至 460.00 美元。Canaccord Genuity Group 在周五将 Madrigal Pharmaceuticals 的目标价从 394.00 美元上调至 420.00 美元，并给予该股票 “买入” 评级。HC Wainwright 在 2 月 27 日的研究报告中将 Madrigal Pharmaceuticals 的目标价从 400.00 美元上调至 405.00 美元，并给予该股票 “买入” 评级。最后，花旗集团在 2 月 27 日的研究报告中将 Madrigal Pharmaceuticals 的目标价从 378.00 美元上调至 469.00 美元，并给予该股票 “买入” 评级。一位分析师对该股票给予了卖出评级，一位给予了持有评级，九位给予了买入评级。根据 MarketBeat 的数据，Madrigal Pharmaceuticals 目前的平均评级为 “适度买入”，平均目标价为 416.33 美元。</p>
<ul>
<li>7 只将推动减肥药市场的股票</li>
</ul>
<p><strong>阅读我们关于 Madrigal Pharmaceuticals 的最新股票报告</strong></p>
<h2>内部人士买卖</h2>
<p>在其他消息中，副总裁 Robert E. Waltermire 在 3 月 5 日的交易中出售了 14,113 股公司的股票。这些股票以平均价格 341.32 美元出售，总价值为 4,817,049.16 美元。出售后，副总裁现在直接持有 3,728 股公司的股票，价值 1,272,440.96 美元。这代表了其持仓的 79.10% 的减少。该交易在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站访问。此外，董事 James M. Daly 在 2 月 27 日的交易中出售了 15,470 股公司的股票。这些股票以平均价格 347.45 美元出售，总交易额为 5,375,051.50 美元。交易后，董事现在直接持有 1,912 股公司的股票，价值约 664,324.40 美元。这笔交易代表了其持仓的 89.00% 的减少。该出售的披露信息可以在这里找到。内部人士在上个季度出售了 30,810 股公司股票，价值 10,610,594 美元。22.80% 的股票目前由公司内部人士持有。</p>
<h2>Madrigal Pharmaceuticals 股票下跌 3.7%</h2>
<ul>
<li>分析师预计这两只中型生物科技股票将获得超过 50% 的收益</li>
</ul>
<p>MDGL 股票在周五开盘价为 315.48 美元。该公司的速动比率为 5.93，流动比率为 5.98，债务与股本比率为 0.15。Madrigal Pharmaceuticals, Inc.的 52 周低点为 200.08 美元，52 周高点为 377.46 美元。该股票的市值为 69.7 亿美元，市盈率为-12.58，贝塔值为-0.69。该公司有 50 日移动平均线为 325.65 美元，200 日移动平均线为 313.96 美元。</p>
<p>Madrigal Pharmaceuticals（NASDAQ:MDGL - 获取免费报告）最近在 5 月 1 日公布了其季度财报。该生物制药公司报告本季度每股收益为（3.32 美元），超过分析师一致预期的（3.62 美元）0.30 美元。该公司本季度的收入为 1.3725 亿美元，而分析师的预期为 1.1279 亿美元。在去年同期，该公司每股收益为（7.38 美元）。卖方分析师预测 Madrigal Pharmaceuticals, Inc.在本年度将发布-23.47 美元的每股收益。</p>
<h2>Madrigal Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Madrigal Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于开发用于治疗美国非酒精性脂肪肝炎（NASH）的治疗药物。其主要产品候选药物为 resmetirom，一种针对肝脏的甲状腺激素受体β激动剂，目前正在进行 NASH 的第三阶段临床试验。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票，而非 Madrigal Pharmaceuticals</li>
<li>大型股的定义及投资方式</li>
<li>Meta 在第一季度财报中表现出色 - 注意第二季度的关税影响</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>亚马逊财报：两个值得喜爱的理由，一个需要谨慎的理由</li>
<li>CD 计算器：定期存款计算器</li>
<li>Palantir 财报：一个看涨信号和一个关注领域</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Madrigal Pharmaceuticals 吗？</h2>
<p>在考虑 Madrigal Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Madrigal Pharmaceuticals 并不在名单上。</p>
<p>虽然 Madrigal Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Madrigal制药

VOYA

<p>Voya Investment Management LLC 在第四季度将其在 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 的持股减少了 77.2%，出售了 33,672 股。出售后，Voya 持有 9,942 股，价值约 307 万美元。其他机构投资者也调整了他们的持股，FMR LLC 增加了 10.8% 的持股。分析师对 MDGL 维持 “适度买入” 的评级，平均目标价为 416.33 美元。近期内部交易中，公司高管进行了大量股票出售，导致股价下跌了 3.7%</p>

<p>Voya Investment Management LLC cut its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 77.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,942 shares of the biopharmaceutical company's stock after selling 33,672 shares during the period. Voya Investment Management LLC's holdings in Madrigal Pharmaceuticals were worth $3,068,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Voya Investment Management LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第四季度将其在 Madrigal Pharmaceuticals, Inc.（NASDAQ:MDGL - 免费报告）中的股份削减了 77.2%。该基金在此期间售出了 33,672 股后，持有 9,942 股该生物制药公司的股票。Voya Investment Management LLC 在 Madrigal Pharmaceuticals 的持股在最近一个季度末价值 306.8 万美元。</p>
</div><ul>
<li>Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德：GLP-1 销售的新动力即将到来</li>
</ul>
</div><p>Other institutional investors also recently added to or reduced their stakes in the company. FMR LLC grew its stake in Madrigal Pharmaceuticals by 10.8% in the 4th quarter. FMR LLC now owns 867,850 shares of the biopharmaceutical company's stock worth $267,792,000 after acquiring an additional 84,305 shares in the last quarter. Geode Capital Management LLC grew its stake in Madrigal Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 410,578 shares of the biopharmaceutical company's stock worth $126,719,000 after purchasing an additional 4,923 shares in the last quarter. William Blair Investment Management LLC purchased a new position in Madrigal Pharmaceuticals during the 4th quarter worth $114,717,000. Rock Springs Capital Management LP raised its position in Madrigal Pharmaceuticals by 0.8% during the 4th quarter. Rock Springs Capital Management LP now owns 265,212 shares of the biopharmaceutical company's stock valued at $81,836,000 after purchasing an additional 2,150 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its holdings in shares of Madrigal Pharmaceuticals by 38.4% in the 4th quarter. Pictet Asset Management Holding SA now owns 208,484 shares of the biopharmaceutical company's stock worth $64,332,000 after buying an additional 57,886 shares during the period. Hedge funds and other institutional investors own 98.50% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者最近也增持或减持了该公司的股份。FMR LLC 在第四季度将其在 Madrigal Pharmaceuticals 的股份增加了 10.8%。FMR LLC 目前持有 867,850 股该生物制药公司的股票，价值 267,792,000 美元，此前在上个季度增持了 84,305 股。Geode Capital Management LLC 在第四季度将其在 Madrigal Pharmaceuticals 的股份增加了 1.2%。Geode Capital Management LLC 目前持有 410,578 股该生物制药公司的股票，价值 126,719,000 美元，此前增持了 4,923 股。William Blair Investment Management LLC 在第四季度购买了 Madrigal Pharmaceuticals 的新头寸，价值 114,717,000 美元。Rock Springs Capital Management LP 在第四季度将其在 Madrigal Pharmaceuticals 的持仓提高了 0.8%。Rock Springs Capital Management LP 目前持有 265,212 股该生物制药公司的股票，价值 81,836,000 美元，此前增持了 2,150 股。最后，Pictet Asset Management Holding SA 在第四季度将其在 Madrigal Pharmaceuticals 的持股提高了 38.4%。Pictet Asset Management Holding SA 目前持有 208,484 股该生物制药公司的股票，价值 64,332,000 美元，此前增持了 57,886 股。对冲基金和其他机构投资者持有该公司 98.50% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>MDGL has been the subject of a number of research reports. JMP Securities reaffirmed a &#34;market outperform&#34; rating and issued a $443.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Thursday, April 24th. B. Riley reissued a &#34;buy&#34; rating and set a $460.00 price objective (up from $422.00) on shares of Madrigal Pharmaceuticals in a report on Friday. Canaccord Genuity Group upped their target price on Madrigal Pharmaceuticals from $394.00 to $420.00 and gave the stock a &#34;buy&#34; rating in a report on Friday. HC Wainwright boosted their price target on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, February 27th. Finally, Citigroup upped their price objective on Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Madrigal Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $416.33.</p>
<div class="lb-trans"><p>MDGL 已经成为多份研究报告的主题。JMP Securities 在 4 月 24 日的研究报告中重申了对 Madrigal Pharmaceuticals 的 “市场表现优于大盘” 评级，并给出了 443.00 美元的目标价。B. Riley 在周五重新发布了 “买入” 评级，并将 Madrigal Pharmaceuticals 的目标价从 422.00 美元上调至 460.00 美元。Canaccord Genuity Group 在周五将 Madrigal Pharmaceuticals 的目标价从 394.00 美元上调至 420.00 美元，并给予该股票 “买入” 评级。HC Wainwright 在 2 月 27 日的研究报告中将 Madrigal Pharmaceuticals 的目标价从 400.00 美元上调至 405.00 美元，并给予该股票 “买入” 评级。最后，花旗集团在 2 月 27 日的研究报告中将 Madrigal Pharmaceuticals 的目标价从 378.00 美元上调至 469.00 美元，并给予该股票 “买入” 评级。一位分析师对该股票给予了卖出评级，一位给予了持有评级，九位给予了买入评级。根据 MarketBeat 的数据，Madrigal Pharmaceuticals 目前的平均评级为 “适度买入”，平均目标价为 416.33 美元。</p>
</div><ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><ul>
<li>7 只将推动减肥药市场的股票</li>
</ul>
</div><p><strong>Read Our Latest Stock Report on Madrigal Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Madrigal Pharmaceuticals 的最新股票报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other news, VP Robert E. Waltermire sold 14,113 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $341.32, for a total value of $4,817,049.16. Following the sale, the vice president now directly owns 3,728 shares of the company's stock, valued at $1,272,440.96. This represents a 79.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, Director James M. Daly sold 15,470 shares of the firm's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $347.45, for a total transaction of $5,375,051.50. Following the transaction, the director now directly owns 1,912 shares of the company's stock, valued at approximately $664,324.40. This trade represents a 89.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,810 shares of company stock valued at $10,610,594 over the last quarter. 22.80% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，副总裁 Robert E. Waltermire 在 3 月 5 日的交易中出售了 14,113 股公司的股票。这些股票以平均价格 341.32 美元出售，总价值为 4,817,049.16 美元。出售后，副总裁现在直接持有 3,728 股公司的股票，价值 1,272,440.96 美元。这代表了其持仓的 79.10% 的减少。该交易在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站访问。此外，董事 James M. Daly 在 2 月 27 日的交易中出售了 15,470 股公司的股票。这些股票以平均价格 347.45 美元出售，总交易额为 5,375,051.50 美元。交易后，董事现在直接持有 1,912 股公司的股票，价值约 664,324.40 美元。这笔交易代表了其持仓的 89.00% 的减少。该出售的披露信息可以在这里找到。内部人士在上个季度出售了 30,810 股公司股票，价值 10,610,594 美元。22.80% 的股票目前由公司内部人士持有。</p>
</div><h2>Madrigal Pharmaceuticals Stock Down 3.7 %</h2>
<div class="lb-trans"><h2>Madrigal Pharmaceuticals 股票下跌 3.7%</h2>
</div><ul>
<li>Analysts see over 50% gains in these 2 mid-cap biotech stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师预计这两只中型生物科技股票将获得超过 50% 的收益</li>
</ul>
</div><p>MDGL stock opened at $315.48 on Friday. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. Madrigal Pharmaceuticals, Inc. has a 52 week low of $200.08 and a 52 week high of $377.46. The stock has a market capitalization of $6.97 billion, a PE ratio of -12.58 and a beta of -0.69. The firm has a 50 day moving average of $325.65 and a 200 day moving average of $313.96.</p>
<div class="lb-trans"><p>MDGL 股票在周五开盘价为 315.48 美元。该公司的速动比率为 5.93，流动比率为 5.98，债务与股本比率为 0.15。Madrigal Pharmaceuticals, Inc.的 52 周低点为 200.08 美元，52 周高点为 377.46 美元。该股票的市值为 69.7 亿美元，市盈率为-12.58，贝塔值为-0.69。该公司有 50 日移动平均线为 325.65 美元，200 日移动平均线为 313.96 美元。</p>
</div><p>Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($3.32) earnings per share for the quarter, beating analysts' consensus estimates of ($3.62) by $0.30. The company had revenue of $137.25 million for the quarter, compared to analysts' expectations of $112.79 million. During the same period last year, the firm earned ($7.38) earnings per share. Sell-side analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals（NASDAQ:MDGL - 获取免费报告）最近在 5 月 1 日公布了其季度财报。该生物制药公司报告本季度每股收益为（3.32 美元），超过分析师一致预期的（3.62 美元）0.30 美元。该公司本季度的收入为 1.3725 亿美元，而分析师的预期为 1.1279 亿美元。在去年同期，该公司每股收益为（7.38 美元）。卖方分析师预测 Madrigal Pharmaceuticals, Inc.在本年度将发布-23.47 美元的每股收益。</p>
</div><h2>Madrigal Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Madrigal Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.</p>
<div class="lb-trans"><p>Madrigal Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，专注于开发用于治疗美国非酒精性脂肪肝炎（NASH）的治疗药物。其主要产品候选药物为 resmetirom，一种针对肝脏的甲状腺激素受体β激动剂，目前正在进行 NASH 的第三阶段临床试验。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Madrigal Pharmaceuticals</li>
<li>Large Cap Stock Definition and How to Invest</li>
<li>Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2</li>
<li>Canadian Penny Stocks: Can They Make You Rich?</li>
<li>Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Palantir Earnings: 1 Bullish Signal and 1 Area of Concern</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Madrigal Pharmaceuticals</li>
<li>大型股的定义及投资方式</li>
<li>Meta 在第一季度财报中表现出色 - 注意第二季度的关税影响</li>
<li>加拿大便士股票：它们能让你致富吗？</li>
<li>亚马逊财报：两个值得喜爱的理由，一个需要谨慎的理由</li>
<li>CD 计算器：定期存款计算器</li>
<li>Palantir 财报：一个看涨信号和一个关注领域</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURHTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MDGL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Madrigal Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Madrigal Pharmaceuticals 吗？</h2>
</div><p>Before you consider Madrigal Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Madrigal Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Madrigal Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Madrigal Pharmaceuticals 并不在名单上。</p>
</div><p>While Madrigal Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Madrigal Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Voya Investment Management LLC 出售了 33,672 股 Madrigal 制药公司（纳斯达克代码：MDGL）的股票